News
Phase III Clinical Trial of the Innovative Drug-Antimicrobial Peptide PL-5 Spray Was Launched

Phase III Clinical Trial of the Innovative Drug-Antimicrobial Peptide PL-5 Spray Was Launched

On August 19, 2021, the “National Conference of Researchers on Phase III Clinical Trial of antimicrobial peptide PL-5 Spray in the treatment of secondary wound infection” was successfully held, marking that the clinical trial of the National “12th Five-Year Plan” and “13th Five-Year Plan” Mega-Projects for Innovative Drugs of China and the national category I innovative drug PL-5 officially will enter the home-stretch phase.

27

2021

/

08

Love, Public Welfare and Warmth 2021-06-15 On June 3 and 4, 2021,

Love, Public Welfare and Warmth 2021-06-15 On June 3 and 4, 2021,

Protelight Pharma paid a visit to the Jiangyin fire brigade, Chengdong police station and Chengdong sanitation station, donated products to firefighters, police and sanitation workers who worked hard, and expressed thanks for their hard work!

15

2021

/

06

Phase IIb Clinical Trial of Antimicrobial Peptide PL-5 Spray was Launched on 2020-07-26

Phase IIb Clinical Trial of Antimicrobial Peptide PL-5 Spray was Launched on 2020-07-26

On July 25, 2020, the “National Conference of Researchers on Phase IIb Clinical Trial of antimicrobial peptide PL-5 spray in the treatment of open wound infection" was successfully held in Shenzhen, marking that the National “12th Five-Year Plan” and “13th Five-Year Plan” Mega-Projects for Innovative Drugs of China and the national category I new drug PL-5 clinical trial officially entered the acceleration phase.

26

2020

/

07

ProteLight Pharma was named the “Potential Unicorn Enterprise of Sunan National Innovation Park” 2019-11-18

ProteLight Pharma was named the “Potential Unicorn Enterprise of Sunan National Innovation Park” 2019-11-18

On Nov. 4th, 2019, sponsored by the government of Jiangsu province, “the 7th Jiangsu Cooperation Conference between Industry and Research” was held in Nanjing. Over 400 experts from 150 universities and more than 2500 enterprises participated in this conference.

18

2019

/

11

New Origin, New Journey – ProteLight Pharma Industry Base Formally Opens 2019-09-23

New Origin, New Journey – ProteLight Pharma Industry Base Formally Opens 2019-09-23

In the morning of September 20, 2019, leaders from Wuxi Government and guests from domestic and abroad arrived to attend the Grand Opening Ceremony of Phase I of ProteLight Pharma Industry Base.

23

2019

/

09

ProteLignt Pharma Honored as “Wuxin Prospective Unicorn Enterprise in 2019”

ProteLignt Pharma Honored as “Wuxin Prospective Unicorn Enterprise in 2019”

On August 30, 2019, ProteLight Pharma was honored as the “Wuxin Prospective Unicorn Enterprise in 2019”.

09

2019

/

09

ProteLight Pharma Completed B Round Capital Raising of RMB 133 million

ProteLight Pharma Completed B Round Capital Raising of RMB 133 million

Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. recently completed the Round B fund-raising of total RMB 133 million yuan, led by a well-known domestic VC firm with outstanding reputation focusing in the field of biological medicine, and jointly invested by local enterprises in Jiangyin. The financing capital of this round is mainly used for the research and development of antimicrobial peptide innovative drugs, the application of clinical approval, clinical trials and related costs of product manufacture. The success of this round of financing will speed up the development of innovative drugs and explore the research depth of antimicrobial peptides. Meanwhile, it will help to expand the influence of the company, market competitiveness and industry scale in the field of antimicrobial peptides. The antimicrobial peptide PL-5 spray project has now entered the Phase II clinical trial. The antimicrobial peptide PL-5 spray project was selected into the national“12th Five-Year Plan” and “13th Five-Year Plan”Mega-Projects for Innovative Drugs of China.

21

2018

/

11

ProteLight Pharma Focuses on R & D of Antimicrobial Peptide New Drugs -- Declare War on “Superbugs”

ProteLight Pharma Focuses on R & D of Antimicrobial Peptide New Drugs -- Declare War on “Superbugs”

September 3th, 2019, “Economic Daily News•China Economic Net” published an article named “ProteLight focuses on R & D of antimicrobial peptide new drugs -- declare war on superbugs", it tells the hard R&D process about Dr. Yuxin Chen, the Chairman of Board of ProteLight Pharma, lead his team to develop antimicrobial peptide new drugs.

05

2018

/

09

< 12345 >